Obesity Management

Data from a pair of phase 2 trials in patients with overweight/obesity and type 2 diabetes presented at ADA 2023 suggest the GIP/GLP-1/Glucagon agonist retatrutide could provide significant weight loss and glycemic control benefits.

Data from a pair of trials presented at ADA 2023 suggests an upped dose of oral semaglutide could soon be on the horizon, with results supporting use in chronic weight management as well as type 2 diabetes.

At ADA 2023, we sat down with W. Timothy Garvey, MD, to learn more about the safety and efficacy of tirzepatide in the SURMOUNT-2 trial and how the results complement SURMOUNT-1.

Data from SURMOUNT-2 presented at ADA 2023 build on results from the SURMOUNT-1 trial, with results detailing the weight loss achieved with tirzepatide in people with type 2 diabetes and overweight or obesity.

A pair of phase 2 trials presented at ADA 2023 detail the body weight lowering and glycemic control benefits of orforglipron, an oral GLP-1 RA developed by Eli Lilly and Company.

Data from a phase 2 dose-finding trial from ADA 2023 suggests use of survodutide was associated with a mean body weight reduction of 14.9% at 46 weeks, with 67% of people using survodutide 4.8 mg losing 15% or more of their baseline body weight.

To celebrate the 10-year anniversary of the AMA recognizing obesity as a disease, this feature leverages the perspective of key opinion leaders to examine what has changed and what has not since the AMA's declaration in June 2013.

A matched case-control study of nearly 100 women details the reduced effect of anti-obesity medications in those with a history of breast cancer and aromatase inhibitor use.

Based on the results of 2 studies, lower birthweight was associated with younger age, lower prevalence of obesity, and fewer individuals with a family history of T2D.

Research presented at ENDO 2023 suggests a high number of adults in the United States with normal BMI still have obesity.

In this episode of MEDcast, Diana Isaacs and Natalie Bellini interview Dr. Ken Fujioka, an endocrine specialist, to discuss practice guidelines on obesity treatment and the evolution of anti-obesity medications over the last decade.

Data from the COVID-OUT trial suggests use of metformin could reduce a person's risk of developing long COVID by more than 50% relative to placebo therapy, with results also providing insight into the apparent lack of benefit with ivermectin and fluvoxamine.

An analysis of nationwide data in Singapore suggests obesity is set to become the leading metabolic risk factor underlying acute myocardial infarction onset, overtaking hypertension and hyperlipidemia in the coming decades.

The ongoing shortage of GLP-1 receptor agonists, namely semaglutide, has prompted the US Food and Drug Administration to issue a warning to patients and providers related to use of compounded semaglutide.

The changes in sleep quality were notably associated with a higher prevalence of obesity indicators in men following the COVID-19 outbreak.

An analysis of data from the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program provides an overview of changing rates of access and utilization of metabolic and bariatric surgery among US youths.

Clinical trial data suggest overweight and obese patients with atrial fibrillation who lose weight prior to a catheter ablation procedure experience better clinical outcomes.

Lungcast hits the road, as the director of pulmonary and critical care medicine at University of Vermont joins to discuss ATS 2023 headlines and the Airways Clinical Research Network.

Phase 2 data suggest the oral small-molecule GLP-1R agonist reduced HbA1c at all dose levels studied and reduced body weight at doses of ≥80 mg twice daily compared with placebo in adults with T2D.

A new analysis found differences in the gut bacteria seen in adults with obesity, suggesting that changes in the gut microbiota that predispose to adult obesity may begin in early childhood.

Despite stable rates of heavy alcohol use, deaths from alcohol-associated liver damage have risen in the US. A new study suggests an increase in the damaging effects of alcohol use in people with metabolic syndrome could be driving this apparent increase.

Announced on May 10, 2023, topline results of the phase 2 dose-finding trial for BI 456906 suggests use was associated with reductions in body weight of up to 14.9% during the 46-week study.

In this episode, hosts offer their reaction to topline data from the SURMOUNT-2 trial examining tirzepatide for weight management in T2D, the FDA's clearance of the Omnipod GO device, and results of the CLVer trial.

Data indicate higher BMI is associated with an increased risk of severe respiratory disease, including COVID-19, with the highest risk observed in those with a BMI in the range of 35-60.

Data from the SURMOUNT-2 trial demonstrate use of tirzepatide 10 mg and 15 mg were associated with mean weight reductions of 13.4% and 15.7%, respectively, with more than 80% of tirzepatide users achieving a body weight reduction of 5% or greater.